Matthew M. Bennett J.D. serves as Independent Director of the Company. He serves as a Managing Director of New Mountain Capital, LLC (“NMC”), and he joined that organization in 2007. Mr. Bennett serves on the board of directors of CIOX Health, Gelest and Cytel and also works closely with other NMC companies. Mr. Bennett previously served as Chief Executive Officer of CIOX Health and before that, he served as Executive Vice President, Global Medical Operations and Chief Legal Officer for Ikaria, Inc. (“Ikaria”), where he served in additional executive roles, including Chief Financial Officer and head of Corporate Development. Prior to joining Ikaria, Mr. Bennett served as Executive Vice President, Chief Administrative Officer, and Chief Business Officer at VIASYS Healthcare, Inc. (NYSE: VAS) (“VIASYS”), where he was responsible for the company’s growth and mergers and acquisitions. Prior to VIASYS, Mr. Bennett served as an advisor on mergers and acquisitions, initial public offerings, and commercial transactions in the health care field at Morgan, Lewis & Bockius LLP, and a litigator in the health care area at Stradley, Ronon, Stevens & Young. Mr. Bennett holds an A.B. in Political Science from Princeton University and a J.D. from Villanova University School of Law.
As the Independent Director of Bellerophon Therapeutics Inc, the total compensation of Matthew Bennett at Bellerophon Therapeutics Inc is $56,324. There are 10 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of $1,400,000.
Matthew Bennett is 48, he's been the Independent Director of Bellerophon Therapeutics Inc since 2018. There are 8 older and 8 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
Matthew's mailing address filed with the SEC is 227 Washington St, Conshohocken, PA 19428, USA.
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein и Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include: